Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...310311312313314315316317318319320...10671068»
  • ||||||||||  hydrocortisone / Generic mfg., epinephrine / Generic mfg.
    Clinical, Journal:  Physiologic effects of stress dose corticosteroids in in-hospital cardiac arrest (CORTICA): A randomized clinical trial. (Pubmed Central) -  Jun 4, 2022   
    P1/2
    We conducted a two-center, randomized, double-blind trial of patients with adrenaline (epinephrine)-requiring cardiac arrest...Postresuscitation shock was treated with hydrocortisone 240 mg daily for 7 days maximum and gradual taper (steroids group), or saline-placebo (control group)...There was no between-group difference in body temperature, echocardiographic variables, prefrontal blood flow index/cerebral autoregulation, organ failure-free days, and hazard for poor in-hospital/functional outcome, and adverse events (P = 0.08->0.99). Our results do not support the use of low-dose corticosteroids in in-hospital cardiac arrest.Trial Registration:ClinicalTrials.gov number: NCT02790788 ( https://www.clinicaltrials.gov ).
  • ||||||||||  Zyesami IV (aviptadil intravenous) / Relief Therap, NRx Pharma
    Enrollment closed:  TESICO: ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (clinicaltrials.gov) -  Jun 3, 2022   
    P3,  N=640, Active, not recruiting, 
    Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Recruiting --> Active, not recruiting
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Jun 3, 2022   
    P1,  N=7, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=24 --> 7 | Trial completion date: Jul 2022 --> Aug 2021 | Trial primary completion date: May 2022 --> Aug 2021
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Trial suspension, Surgery:  The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery (clinicaltrials.gov) -  Jun 3, 2022   
    P1,  N=87, Suspended, 
    Recruiting --> Completed | N=24 --> 7 | Trial completion date: Jul 2022 --> Aug 2021 | Trial primary completion date: May 2022 --> Aug 2021 Recruiting --> Suspended
  • ||||||||||  19 Year Old Wrestler With Altered Mental Status (31A) -  Jun 2, 2022 - Abstract #ACSM2022ACSM_1323;    
    CT 11/3: Interval development of increased sulcal crowding of the bilateral cerebral convexities concerning for mild diffuse cerebral edema. MRI 10/18: Subtle cortical edema is suggested diffusely that can be seen with encephalitis versus seizure activity.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion date, Trial primary completion date, Combination therapy:  Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov) -  Jun 2, 2022   
    P1/2,  N=66, Recruiting, 
    MRI 10/18: Subtle cortical edema is suggested diffusely that can be seen with encephalitis versus seizure activity. Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Apr 2027 --> Oct 2027
  • ||||||||||  dexamethasone / Generic mfg., clonidine / Generic mfg., epinephrine / Generic mfg.
    Trial completion date, Trial primary completion date, Surgery:  RCT Comparing ESPB Solutions in Breast Surgery (clinicaltrials.gov) -  Jun 2, 2022   
    P2,  N=75, Recruiting, 
    Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Apr 2027 --> Oct 2027 Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Dec 2022
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Neuroimaging Mechanisms by Which Memory and Glucocorticoids Promote Risky Drinking (clinicaltrials.gov) -  Jun 2, 2022   
    P1,  N=27, Completed, 
    Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Dec 2022 Recruiting --> Completed | Trial completion date: Jun 2023 --> Mar 2022 | Trial primary completion date: Jun 2023 --> Mar 2022
  • ||||||||||  Opdivo (nivolumab) / BMS, Reolysin (pelareorep) / Oncolytics, Andrus Reo
    Enrollment closed, Enrollment change, Trial primary completion date, Oncolytic virus:  Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) -  Jun 1, 2022   
    P1,  N=23, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=62 --> 23 | Trial primary completion date: May 2022 --> May 2023
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion:  CIDEX: Dexamethasone-Eluting Cochlear Implant Electrode (clinicaltrials.gov) -  Jun 1, 2022   
    P=N/A,  N=10, Completed, 
    Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023 Active, not recruiting --> Completed
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Journal:  Responding to COVID-19 Through Interhospital Resource Coordination: A Mixed-Methods Evaluation. (Pubmed Central) -  May 31, 2022   
    Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2021 With standardized communication, interhospital transfers can be a safe and effective method of cohorting COVID-19 patients, are well received by health care providers, and have the potential to improve care quality.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Protective effect of Naringin ameliorates TNBS-induced colitis in rats via improving antioxidant status and pro-inflammatory cytokines. (Pubmed Central) -  May 31, 2022   
    Forty-two male Wistar rats were divided into seven groups like Normal Control (NC), Ethanol Control (EC), Disease Control (DC), NG 20 (20 mg/kg, p.o.), NG 40 (40 mg/kg, p.o.), NG 80 (80 mg/kg, p.o.), and Dexamethasone (DEX) (2 mg/kg, p.o.)...Our results demonstrated that NG treatment attenuated pathologic changes of TNBS-induced colitis in rats through restoring colonic damage and reducing inflammatory response in the colon tissue. Thus, NG might be considered as an effective candidate for the treatment of UC patients.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Emerging treatment for congenital adrenal hyperplasia. (Pubmed Central) -  May 31, 2022   
    Trials of corticotropin releasing hormone receptor antagonists and androgen biosynthesis inhibitors are currently underway. The author believes that trials of gene therapy for CAH are premature.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date:  Anosmia and / or Ageusia and Early Corticosteroid Use (clinicaltrials.gov) -  May 31, 2022   
    P4,  N=300, Recruiting, 
    Studies stratifying DST non-suppressors according to established dosage-regimens in somatic settings are needed to fully elucidate the putative contribution of HPA-axis dysregulation to EA. Trial completion date: May 2022 --> Oct 2022
  • ||||||||||  Veramyst (fluticasone furoate nasal spray) / GSK
    Trial primary completion date:  ACTIV-6: COVID-19 Study of Repurposed Medications (clinicaltrials.gov) -  May 30, 2022   
    P3,  N=15000, Recruiting, 
    Trial completion date: May 2022 --> Oct 2022 Trial primary completion date: Dec 2022 --> Mar 2023